VolitionRx Launches Sepsis Detection Program in France with €6.3M Government Funding
Event summary
- VolitionRx's Nu.Q® NETs H3.1 biomarker integrated into the DETECSEPS program for early sepsis detection in French emergency departments.
- €6.3 million government-funded project to evaluate the strategy in 1,000 patients across AP-HP and Hospices Civils de Lyon.
- Combination of NEWS 2 clinical score, Nu.Q® NETs H3.1 biomarker, and IDS i10 device for rapid sepsis risk assessment.
- Project aims to reduce hospitalizations, improve emergency department efficiency, and lower socio-economic costs.
- VolitionRx providing the biomarker pro-bono for this evaluation.
The big picture
This initiative represents a significant validation of VolitionRx's epigenetics platform in a critical care application beyond oncology. The €6.3 million government backing underscores the strategic importance of early sepsis detection in reducing healthcare costs and improving patient outcomes. Success in this program could position VolitionRx as a key player in infectious disease diagnostics, expanding its addressable market beyond cancer.
What we're watching
- Clinical Validation
- Whether Nu.Q® NETs H3.1 can demonstrate sufficient accuracy and reliability in real-world emergency settings to justify broader adoption.
- Regulatory Pathway
- The pace at which VolitionRx can navigate regulatory approvals for sepsis detection applications following successful trial results.
- Commercialization Strategy
- How VolitionRx plans to monetize this technology if proven effective, particularly in competitive sepsis diagnostics market.
Related topics